Parliamentary questions

1833. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken regarding regional variation in SCAN eligibility decisions or referral acceptance practices. [41700/26]

1834. Deputy Ken O'Flynn asked the Minister for Health whether the forthcoming SCAN KPI framework will include data relating to rejected, redirected, or ineligible referrals. [41701/26]

1835. Deputy Ken O'Flynn asked the Minister for Health whether consideration is being given to establishing a nationally standardised dataset for referrals not accepted into SCAN services. [41702/26]

1836. Deputy Ken O'Flynn asked the Minister for Health whether any adverse incident review process exists where a person deemed ineligible for SCAN services subsequently presents in crisis, self-harms, or requires emergency intervention. [41703/26]

1837. Deputy Ken O'Flynn asked the Minister for Health whether SCAN services currently operate under nationally standardised eligibility criteria and whether these criteria are publicly available. [41704/26]

1838. Deputy Ken O'Flynn asked the Minister for Health whether any audit has been undertaken into onward referral pathways for persons not accepted into SCAN services. [41705/26]

1839. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has undertaken any modelling of the projected annual eligible population for reimbursement of tirzepatide or semaglutide for obesity treatment over the next five years. [41712/26]

1840. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the potential annual Exchequer cost associated with reimbursement of obesity pharmacotherapies under current licensing criteria. [41713/26]

1841. Deputy Ken O'Flynn asked the Minister for Health whether any national eligibility framework, prioritisation framework, or phased access model is under development for obesity pharmacotherapy reimbursement. [41714/26]

1842. Deputy Ken O'Flynn asked the Minister for Health whether multidisciplinary assessment, psychological screening, or behavioural intervention participation will be mandatory prior to reimbursement approval for obesity pharmacotherapies. [41715/26]

1843. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken of the long-term fiscal sustainability of reimbursing GLP-1 and dual agonist obesity therapies within the public health system. [41716/26]

1844. Deputy Ken O'Flynn asked the Minister for Health whether any formal safeguards or governance framework are being developed in relation to proposed reimbursement pathways for obesity pharmacotherapies in adolescent patients. [41717/26]

1845. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the projected number of adolescent patients who could potentially meet the proposed reimbursement criteria for semaglutide. [41718/26]

1846. Deputy Michael Cahill asked the Minister for Health if she will urgently meet with a professional oversight body (details supplied); and if she will make a statement on the matter. [41724/26]

1847. Deputy Seán Crowe asked the Minister for Health the number of WTEs in children’s respite services in the CHO7 area each year for the past five years, in tabular form. [41732/26]

1848. Deputy Seán Crowe asked the Minister for Health the number of properties that are in use for the provision of children’s respite services in the CHO7 area each year for the past five years, in tabular form. [41733/26]

1849. Deputy Seán Crowe asked the Minister for Health to report on the sale of a property (details supplied) which is being sold despite its former use and suitability for children’s respite services. [41734/26]

1850. Deputy Ken O'Flynn asked the Minister for Health to outline what the end-to-end process review will entail under Schedule 4 of the revised IPHA Framework Agreement; the expected terms of reference for the review; how stakeholders and members of the public will be able to feed into the review; and if she will make a statement on the matter. [41756/26]

1851. Deputy Ken O'Flynn asked the Minister for Health when she expects to publish the new diabetes strategy; and if she will make a statement on the matter. [41757/26]

1852. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any internal operational guidance, assessment template, decision-support document, evidential framework, or staff instruction document used in practice when determining eligibility under the treatment abroad scheme; and if so, if copies will be provided. [41759/26]

1853. Deputy Ken O'Flynn asked the Minister for Health whether any formal mechanism exists within the treatment abroad scheme to ensure consistency of eligibility decisions between applicants presenting with comparable clinical circumstances; and if they will outline that mechanism. [41760/26]

1854. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit, external audit, clinical governance review, or value-for-money review has examined treatment abroad scheme eligibility decision-making processes since 2020; and if so, to provide details and publication status. [41761/26]

1855. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains written evidential thresholds or documentary standards required before prior authorisation may be approved under the treatment abroad scheme; and if they will provide details. [41762/26]

1856. Deputy Ken O'Flynn asked the Minister for Health whether treatment abroad scheme approval decisions are subject to secondary review, peer review, multidisciplinary review, or independent oversight before final authorisation is granted. [41763/26]

1857. Deputy Ken O'Flynn asked the Minister for Health whether all categories of treatment funded under the treatment abroad scheme are subject to identical governance, evidential, audit, and approval standards; and if any category-specific governance arrangements exist. [41764/26]